Abstract Number: 2549 • 2013 ACR/ARHP Annual Meeting
Can Biomarkers Provide An Objective Standard Against Which To Assess Lupus Clinical Endpoint Measures?
Background/Purpose: Despite the heterogeneity of SLE, specific pathways of immune dysregulation characterize significant subsets of patients. We examined cytokines reflecting IL6-TH17 pathology in lupus as…Abstract Number: 915 • 2013 ACR/ARHP Annual Meeting
IL-6R Inhibition Reduces Activation Of Different Peripheral Memory B Cell Subsets In RA
Background/Purpose: Enhanced B cell activity has been proposed as part of the pathogenesis of rheumatoid arthritis also based on the clinical experiences obtained by B…Abstract Number: 2355 • 2013 ACR/ARHP Annual Meeting
Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Against The IL-6 Receptor Alpha: Using Acute Phase Reactants, Efficacy and Safety Parameters To Inform Phase 3 Dose Selection
Background/Purpose: Sarilumab (SAR) is a fully human mAb directed against IL-6Rα. In phase 2 MOBILITY Part A (NCT01061736), SAR administered SC plus MTX (methotrexate 10-25…Abstract Number: 667 • 2013 ACR/ARHP Annual Meeting
IL6 and CCL2 Co-Regulate Fibroblast Dependent Trans-Endothelial Migration Of Mononuclear Cells and Fibrotic Response In Scleroderma
Background/Purpose: IL6 is a key mediator recently implicated in activation of extracellular matrix (ECM) proteins in scleroderma (SSc) fibroblasts. CCL2 is a proinflammatory chemokine that…Abstract Number: 2358 • 2013 ACR/ARHP Annual Meeting
Sarilumab, a Subcutaneously Administered, Fully Human Monoclonal Antibody Inhibitor Of The IL-6 Receptor Alpha: 12 Week Infection Rates By Level Of Circulating Neutrophils In Rheumatoid Arthritis and Ankylosing Spondylitis
Background/Purpose: Sarilumab is a human monoclonal antibody directed against the alpha subunit of the IL-6 receptor (IL-6Rα). IL-6 blockade is associated with a reduction in…Abstract Number: 653 • 2013 ACR/ARHP Annual Meeting
Norepinephrine-Induced IL-6 Regulates Fibrosis In Systemic Sclerosis
Background/Purpose: Raynaud phenomenon is freaquently observed in patients of systemic sclerosis (SSc) and characterized by episodic vasospasm and ischemia of extremities in response to cold or…Abstract Number: 2263 • 2013 ACR/ARHP Annual Meeting
ADAMTS5 Is a Biomarker For The Efficacy Prediction Of Tocilizumab In Rheumatoid Arthritis
a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) mRNA level. In this study presented here, we investigated whether the efficacy of tocilizumab (TCZ) for…Abstract Number: 558 • 2013 ACR/ARHP Annual Meeting
Fli-1 Regulates Immune Cell Infiltration Through Affecting Local Chemokine Expression and IL-6 Expression In The Kidney Of Lupus Prone Mice
Background/Purpose: Fli-1 expression level, a member of the Ets family of transcription factors, is a mitigating factor in the development of nephritis in murine models…Abstract Number: 2213 • 2013 ACR/ARHP Annual Meeting
Anti-IL-6 Receptor Antibody Normalizes Both DKK-1 and Sclerostin As Wnt Inhibitors In a Mouse Model Of Collagen-Induced Arthritis
Background/Purpose: The Wnt pathway plays an important role in bone formation and regeneration. This pathway is regulated by several soluble inhibitors such as Dickkopf-1 (DKK-1)…Abstract Number: 470 • 2013 ACR/ARHP Annual Meeting
Sarilumab, a Subcutaneously Administered, Fully Human Monoclonal Antibody Inhibitor Of The IL-6 Receptor Alpha: Relationship Between Inflammation Suppression and Changes In Cholesterol Levels
Background/Purpose: Sarilumab (SAR) is a fully human monoclonal antibody directed against the alpha subunit of the IL-6 receptor (IL-6Rα) which is currently being evaluated for…Abstract Number: 2226 • 2013 ACR/ARHP Annual Meeting
Involvement Of Suppressor Of Cytokine Signaling In Anti-Arthritic Effect Induced By Anti-IL-6 Receptor Antibody
Background/Purpose: In the treatment of rheumatoid arthritis (RA), biologics such as IL-6 and TNF inhibitors have high therapeutic efficacy with extended duration of effect [“LITHE…Abstract Number: 436 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Study Of a Sequential Therapy Of Tocilizumab and, If Initially Inadequately Responded To Tocilizumab, Followed By Rituximab In Patients With Rheumatoid Arthritis and Inadequate Response To Traditional Disease Modifying Anti-Rheumatic Drugs (MIRAI)-Interim Analysis 2
Background/Purpose: The MIRAI study evaluates a sequential exposure to two defined biologics under rigorous study conditions within a homogeneous population of patients (pts) who inadequately…Abstract Number: 1855 • 2013 ACR/ARHP Annual Meeting
IL-6 Promotes Systemic Bone Loss Via Upregulation Of S1PR2 In Osteoclast Precursors In a Mouse Collagen-Induced Arthritis Model
Background/Purpose: Systemic bone loss is a hallmark of rheumatoid arthritis (RA). Inflammatory cytokines such as interleukin-6 (IL-6) promote bone resorption by osteoclasts. Recent studies have…Abstract Number: 1866 • 2013 ACR/ARHP Annual Meeting
Primary Human Cell BioMAP® Profiling Of Methotrexate, Tocilizumab, Adalimumab, and Tofacitinib Reveals Different Mechanisms Of Action With Distinct Phenotypic Signatures
Background/Purpose: Proinflammatory cytokines cause joint inflammation and destruction in patients with rheumatoid arthritis, as exemplified by the therapeutic success of inhibiting tumor necrosis factor alpha…Abstract Number: 1833 • 2013 ACR/ARHP Annual Meeting
Combination Of TNF and IL-6 Induces Osteoclast-Like Cells With Bone-Resorption Activity Both In Vitro and In Vivo
Background/Purpose: Although TNF inhibitors suppress bone destruction in patients with rheumatoid arthritis (RA), TNFα stimulation alone does not directly induce osteoclasts, bone-resorbing cells. With the…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- Next Page »